Stock Research: Ikena Oncology

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Ikena Oncology

NasdaqGM:IKNA US45175G1085
24
  • Value
    100
  • Growth
    31
  • Safety
    Safety
    22
  • Combined
    56
  • Sentiment
    57
  • 360° View
    360° View
    24
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Ikena Oncology, Inc. is a clinical-stage, targeted oncology company. The Company is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. Its lead program in the RAS pathway, IK-595, is a molecular glue designed to trap MEK and RAF in an inactive complex, more completely inhibiting RAS signals than existing inhibitors. IK-595’s ability to complex the RAFs, including CRAF prevents a signaling bypass mechanism that cancer cells employ to drive therapeutic resistance to other drugs in this class. IK-595 is being developed as an oral therapy and evaluated in a Phase I clinical trial in RAS and RAF mutant cancers.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 24 (better than 24% compared with alternatives), overall professional sentiment and financial characteristics for the stock Ikena Oncology are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with half below and half above average for Ikena Oncology. The consolidated Sentiment Rank has a good rank of 57, which means that professional investors are more optimistic about the stock than for 57% of alternative investment opportunities. It also rates well regarding its financing structure, with the consolidated Safety Rank at 100 or better than 100% of its peers when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the stock is expensive and expects low growth. The consolidated Value Rank is only 22, meaning that the share price of Ikena Oncology is on the high side, compared with indicators such as revenues, profits, and invested capital. The company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth,and stock returns, with its Growth Rank at 31. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
22 26 36 31
Growth
31 55 27 57
Safety
Safety
100 100 59 59
Sentiment
57 34 51 21
360° View
360° View
24 24 42 21
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
78 75 100 88
Opinions Change
100 50 50 50
Pro Holdings
n/a 46 21 10
Market Pulse
7 7 28 24
Sentiment
57 34 51 21
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
22 26 36 31
Growth
31 55 27 57
Safety Safety
100 100 59 59
Combined
56 56 88 88
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
36 36 36 36
Price vs. Earnings (P/E)
1 1 11 8
Price vs. Book (P/B)
81 79 78 74
Dividend Yield
1 1 1 1
Value
22 26 36 31
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
1 8 4 25
Profit Growth
77 63 42 89
Capital Growth
67 69 69 91
Stock Returns
15 61 41 13
Growth
31 55 27 57
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
100 100 100 100
Refinancing
87 96 97 87
Liquidity
1 1 17 17
Safety Safety
100 100 59 59

Similar Stocks

Discover high‑ranked alternatives to Ikena Oncology and broaden your portfolio horizons.

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.